Exclusivity For Biologics Should Potentially Be Longer Than For Small Molecule Drugs – BIO Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
In debate over follow-on biologics pathway, BIO and GPhA agree on little except the need to lay out intellectual property ground rules.